Hepion Secures $500K Convertible Note with 12.5M Warrants from Gravitas Capital
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals issued a $500,000 secured convertible note to Gravitas Capital LP with 12.5 million warrants attached, adding to a series of recent capital raises as the company works through going concern challenges.
Key Events · Financing and Capital Events · CTRVP
-
Secured Convertible Note Issued
Hepion issued a $500,000 senior secured convertible note to Gravitas Capital LP on September 3, 2026, bearing 8% PIK interest and maturing September 3, 2027.
-
Warrant for 12.5M Shares
The deal includes a warrant to purchase 12,500,000 shares at $0.06 per share, exercisable through September 3, 2031, representing significant potential dilution if exercised.
-
Conversion Terms
The note is convertible at $0.04 per share upon stockholder approval of an authorized share increase, with both conversion and warrant prices well above the current $0.0013 stock price.
-
Asset-Backed Security
The note is secured by all company assets, giving Gravitas priority claim in a default scenario — a notable risk given the going concern warning in the August 10-Q.
Analysis · CTRVP · Life Sciences
On September 3, 2026, Hepion Pharmaceuticals entered into a $500,000 secured convertible note agreement with Gravitas Capital LP. The note carries an 8% PIK interest rate, matures September 3, 2027, and is convertible at $0.04 per share upon stockholder approval of an authorized share increase. The deal also includes a warrant for 12.5 million shares at $0.06 per share, exercisable through September 3, 2031. The note is secured by all company assets. This financing follows a series of recent capital raises totaling over $3.9 million since August, reflecting continued cash needs amid a going concern warning disclosed in the August 10-Q. The conversion price of $0.04 and warrant exercise price of $0.06 are both significantly above the current stock price of $0.0013, meaning the conversion and warrant features are currently out-of-the-money. However, the 12.5 million warrant shares represent substantial potential dilution if the stock price recovers. The secured nature of the note gives Gravitas priority claim on company assets in a default scenario, which is notable given the company's distressed financial position.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.5% of the 1531 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.